Search Results - Russel Burge

Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J) by Masaru Honma, Zhihong Cai, Russel Burge, Baojin Zhu, Sohiya Yotsukura, Hitoe Torisu-Itakura

Connect to this object online.

Assessing the Impact of Improvements in PASI and Itch Scores on Patients' Quality of Life in the Treatment of Psoriasis by Gil Yosipovitch, Yan Dong, Russel Burge, Baojin Zhu, David Shrom, Alexa B. Kimball

Connect to this object online.

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses by Richard B. Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg

Connect to this object online.

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension by Alexandra B. Kimball, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Russel Burge, Chen-Yen Lin, Gil Yosipovitch

Connect to this object online.

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program by Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola

Connect to this object online.

Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey by Joe Gorelick, David Shrom, Kiran Sikand, Lisa Renda, Russel Burge, Christine Dworkin, Craig Krebsbach, Ripsi P. Patel, Chitra Karki, David Rosmarin

Connect to this object online.

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial by Lyn Guenther, Alison Potts Bleakman, Jamie Weisman, Yves Poulin, Lynda Spelman, Russel Burge, Janelle Erickson, Kristin Todd, Clinton C. Bertram, Caitriona Ryan

Connect to this object online.

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by... by Alexander Egeberg, Jason E. Hawkes, Najwa Somani, Russel Burge, Kyoungah See, Gaia Gallo, Missy McKean-Matthews, Melinda Gooderham, George Han, April Armstrong

Connect to this object online.

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)... by Jennifer Soung, Jennifer C. Cather, Melinda Gooderham, Caitriona Ryan, Najwa Somani, Meghan Feely, Kyoungah See, Russel Burge, Mohamed Elrayes, Gaia Gallo, April W. Armstrong

Connect to this object online.

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials by Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher E. M. Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim Papp

Connect to this object online.